Harbour BioMed Raises $75 Million Series B+ Venture Capital Financing to Accelerate Its Innovative Pipeline
Amount Raised
$75 Million
Round Type
Series B
United StatesBiotechnologyTherapeuticsBiopharmaDescription
Harbour BioMed (HBM) today announced successful completion of its Series B+ round financing of $75 million to accelerate the advancement of its clinical-stage compounds and growing portfolio of next generation biotherapeutics for treating cancer and immunological diseases. New investors participating in the financing – SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang Venture Capital and Zhejiang University Future Capital and JT New Century - joined existing investors, including Legend Capital, AdvanTech and GIC Pvt. Ltd. The company previously completed an $85 million Series B financing in August 2018.
Quick answer
Harbour BioMed raised $75 Million in a Series B round, dated March 12, 2020. Harbour BioMed is based in United States.
- How much did Harbour BioMed raise?
- Harbour BioMed raised $75 Million in a Series B round on March 12, 2020.
- What does Harbour BioMed do?
- Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology.
- Where is Harbour BioMed based and how big is it?
- Harbour BioMed is based in United States.
- Who are the decision-makers at Harbour BioMed?
- Fundz holds 5 contacts at Harbour BioMed, including the SVP, Global Head of Legal. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Harbour BioMed that raised within 45 days of this round, from Fundz verified event records.
- Fate Therapeutics raised $50M on April 21, 2020.
- OnKure Therapeutics raised $3.2M (Seed) on April 15, 2020.
- iTeos Therapeutics, Inc. raised $125M on April 9, 2020.
- Nurix Therapeutics raised $120M on March 26, 2020.
- Kymera Therapeutics raised $102M (Series C) on March 12, 2020.
- OnKure Therapeutics raised $1M (Seed) on March 6, 2020.
Who to call at Harbour BioMed, and when
A new round usually means Harbour BioMed is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Harbour BioMed raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Harbour BioMed, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Harbour BioMed. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Harbour BioMed raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansHarbour BioMed raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.